7 results about "Diabetic animal" patented technology

The present application relates to the field of pharmacology, in particular to the use of paeoniflorin-6'-O-benzene sulfonate for improving acinar atrophy, maintaining the stability of gland functional units, and repairing gland secretion function. The paeoniflorin-6'-O-benzene sulfonate can effectively improve the acinar atrophy of diabetic animals, and the effect is significantly better than that of paeoniflorin, and can be used for preparing a medicine for treating xeroma.

The invention discloses a novel BimBH3 mimic peptide analogue constructed on the basis of a nailing and fatty acid acylation dual-modification strategy and application of the novel BimBH3 mimic peptide analogue serving as a PTPN1 inhibitor to development of a long-acting hypoglycemic drug. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The invention provides the BimBH3 mimic peptide analogue with a novel structure, and the BimBH3 mimic peptide analogue is constructed by adopting a nailing and fatty acid acylation dual-modification strategy and has the structural general formula as shown in the formula I. The invention further provides a preparation method of the BimBH3 mimic peptide analogue. On the basis of a BimBH3 functional domain core sequence, the novel BimBH3 mimic peptide analogue has target inhibitory activity, metabolic stability and in-vivo action durability through second-site lysine substitution, N-terminal palmitic acid conjugation and fifth, sixth and ninth site glutamic acid side chain mediated synthesis ring nailing modification, and the synthesis ring nailing mode is molecular lactam cyclization. Experiments show that the compound can efficiently inhibit PTPN1 activity, has a long-acting hypoglycemic effect in a type 2 diabetes animal model, and has the potential of being developed into a long-acting antidiabetic drug which is administered once a week. The invention also discloses a solid-phase synthesis preparation method of the compound and application of the compound as a potential PTPN1 inhibitor drug.

The present application relates to the technical field of hydrogel composite scaffold, in particular to a layer-by-layer self-assembled oxygen-responsive liposome hydrogel composite scaffold and a preparation method, hydrophilic nerve growth factor (GDNF) is encapsulated in the aqueous internal region of the liposome, and low-oxygen-responsive vascular endothelial growth factor (VEGF) plasmid and polyarginine are coated by electrostatic adsorption layer by layer (LBL), so as to construct an intelligent responsive LBL double-drug cationic liposome; subsequently, hyaluronic acid-carboxymethyl cellulose sodium (HA-CMC) hydrogel is introduced to carry the liposome to form a double-drug composite scaffold, so as to enhance the adhesion and local release characteristics of the composite scaffold on the wound surface. In a diabetic animal model, the LBL liposome loaded on the HA / CMC hydrogel can significantly accelerate wound healing, promote collagen deposition, angiogenesis and nerve fiber regeneration, and regulate the polarization of macrophages to the repair phenotype, thereby reducing the inflammatory response and achieving functional tissue repair.

The invention relates to an engineered exosome drug delivery system with enhanced membrane fluidity as well as a preparation method and application of the engineered exosome drug delivery system. According to the system, unsaturated phospholipid is inserted into an exosome membrane, so that the membrane flowability of the exosome is enhanced on the premise of not damaging a natural structure and protein composition, and the entrapment efficiency of polypeptide proteins, nucleic acid and small-molecule chemical drugs is remarkably improved. The membrane fluidity is enhanced, the diffusivity, the cellular uptake efficiency and the transepithelial transport performance of the exosome in intestinal mucus are improved, and the physiological barrier of oral delivery can be effectively overcome. In type I and type II diabetes animal models, the system significantly improves the oral bioavailability of insulin and semaglutide, and shows an excellent blood sugar regulation effect. The preparation method is simple and convenient, the biocompatibility is good, and a novel delivery strategy with a good transformation prospect is provided for oral biological macromolecular and micromolecular chemical drugs.

The application relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model, and relates to the field of experimental animal models, and particularly relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model. The application aims at solving the problems of long modeling time, instability and easy change into a type 1 diabetes mellitus model of the existing type 2 diabetes mellitus animal model establishing method. The feed comprises desulfurization vibrio powder, symbiotic clostridium powder and high-fat high-sugar feed. The method comprises the following steps: drying desulfurization vibrio liquid and symbiotic clostridium liquid into powder, uniformly mixing the powder and the high-fat high-sugar feed, and extruding into a column shape by using an extrusion molding machine. The application significantly shortens the establishment time of the type 2 diabetes mellitus animal model, does not need to inject a high-dose STZ, and does not cause the type 1 diabetes mellitus model of absolute insulin deficiency of rats in the case of using a higher concentration of STZ induction. The induced type 2 diabetes mellitus feed is used for establishing the type 2 diabetes mellitus animal model.

The present disclosure relates to a diabetic animal model and methods of constructing and using the same. In particular, the present disclosure relates to a diabetic animal model, wherein the insulin enhancer binding protein-1 (Isl-1) gene in the genome of the animal model comprises a mutation in an exon and encodes an Isl-1 polypeptide having at least one amino acid substitution compared to a wild-type Isl-1 polypeptide.

The present application provides a preparation method of a non-human mammal model of type 1 diabetes. Specifically, the present application induces islet beta cell destruction in a non-immunodeficient mouse by using T cells specifically targeting GAD, constructs T cell autoimmune type 1 diabetes in line with the actual pathogenesis, and has application prospects in the field of diabetes research.